Stock listing

Stuttgart:HPHA Heidelberg Pharma AG Aktie

German listing (Stuttgart) of Heidelberg Pharma AG · home listing Xetra:HPHA

Follow Heidelberg Pharma AG into a list and get an email when it puts out news.

Home listing price · XETR:HPHA

€2.01 EUR -0.05 (-2.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, XETR:HPHA

Past year -33.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€1.95 – €2.13 EURNov 20, 2026
Volume
4,035 sharesNov 20, 2026
Market cap
€94.04M EURAt the close on Nov 20, 2026 · price × 46.78M shares outstanding
52-week range
€1.95 – €3.34 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€8,921 EURMedian day 1,884 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Heidelberg Pharma AG logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Xetra:HPHA · Home€2.01 EUR-0.05 (-2.4%)4,035€2.13€2.13€1.95€2.06Close on Nov 20, 2026
LSE:0QW5€2.12 EUR+0.06 (+2.9%)6€2.12€2.12€2.12€2.06Close on Nov 20, 2026
Frankfurt:HPHA€2.00 EUR-0.01 (-0.5%)—€2.01€2.01€2.00€2.01Close on Nov 20, 2026
Dusseldorf:HPHA€1.925 EUR-0.075 (-3.7%)—€2.00€2.00€1.925€2.00Close on Nov 20, 2026
Hamburg:HPHA€2.01 EUR0.00 (0.0%)—€2.01€2.01€2.01€2.01Close on Nov 20, 2026
Munich:HPHA€2.08 EUR0.00 (0.0%)—€2.08€2.08€2.08€2.08Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · XETR:HPHA · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€2.01-0.05-2.4%€2.13€2.13€1.954,035
€2.06-0.01-0.5%€2.05€2.06€2.025
€2.07-0.01-0.5%€2.15€2.15€2.001,363
€2.08-0.01-0.5%€2.14€2.14€2.082,991
€2.09+0.05+2.5%€2.10€2.14€2.05224
€2.04-0.08-3.8%€2.10€2.17€2.041,890
€2.12-0.05-2.3%€2.08€2.17€2.081,878
€2.17-0.02-0.9%€2.14€2.17€2.13726
€2.19+0.05+2.3%€2.16€2.19€2.102,634
€2.14+0.09+4.4%€2.06€2.14€2.061,722
€2.05+0.04+2.0%€2.03€2.05€2.012,952
€2.01-0.07-3.4%€2.09€2.09€1.99514,155
€2.08-0.01-0.5%€2.13€2.16€2.011,677
€2.09-0.02-0.9%€2.16€2.16€2.05958
€2.11-0.03-1.4%€2.17€2.20€2.082,620
€2.140.000.0%€2.14€2.20€2.11300
€2.14+0.01+0.5%€2.10€2.17€2.103,970
€2.13+0.05+2.4%€2.10€2.13€2.101,923
€2.08-0.07-3.3%€2.10€2.14€2.02789
€2.15+0.12+5.9%€2.09€2.16€1.989,435
€2.03-0.13-6.0%€2.19€2.19€1.9810,457
€2.16-0.06-2.7%€2.12€2.23€2.112,703
€2.22+0.02+0.9%€2.21€2.23€2.181,783
€2.200.000.0%€2.20€2.21€2.181
€2.20-0.09-3.9%€2.29€2.29€2.157,305
€2.29+0.09+4.1%€2.32€2.33€2.231,533
€2.20-0.05-2.2%€2.29€2.29€2.20840
€2.25-0.02-0.9%€2.34€2.38€2.2019,801
€2.27+0.04+1.8%€2.20€2.33€2.209,080
€2.23-0.05-2.2%€2.27€2.34€2.213,332
€2.28-0.02-0.9%€2.28€2.33€2.222,170
€2.30-0.05-2.1%€2.33€2.33€2.261,057
€2.350.000.0%€2.32€2.35€2.242,072
€2.350.000.0%€2.41€2.41€2.241,306
€2.35-0.01-0.4%€2.36€2.37€2.346,893
€2.360.000.0%€2.43€2.44€2.331,546
€2.36-0.16-6.3%€2.46€2.46€2.3036,335
€2.52-0.06-2.3%€2.40€2.52€2.3021,378
€2.580.000.0%€2.58€2.58€2.441,469
€2.58+0.05+2.0%€2.53€2.58€2.53355
€2.53-0.03-1.2%€2.53€2.53€2.53374
€2.56+0.03+1.2%€2.52€2.56€2.441,818
€2.53+0.04+1.6%€2.50€2.57€2.4410,841
€2.49-0.03-1.2%€2.57€2.57€2.422,696
€2.52-0.02-0.8%€2.54€2.60€2.487,907
€2.54-0.01-0.4%€2.54€2.54€2.50989
€2.55+0.04+1.6%€2.50€2.55€2.50329
€2.51+0.11+4.6%€2.58€2.58€2.482,305
€2.40-0.10-4.0%€2.45€2.61€2.404,112
€2.50+0.05+2.0%€2.40€2.50€2.40958
€2.45-0.05-2.0%€2.46€2.46€2.45104
€2.50-0.05-2.0%€2.50€2.57€2.432,287
€2.55+0.02+0.8%€2.50€2.55€2.46187
€2.530.000.0%€2.58€2.60€2.502,235
€2.53+0.05+2.0%€2.53€2.57€2.461,235
€2.48+0.06+2.5%€2.54€2.56€2.482,994
€2.42-0.13-5.1%€2.50€2.50€2.42219
€2.55+0.05+2.0%€2.70€2.70€2.492,491
€2.50-0.12-4.6%€2.70€2.70€2.502,980
€2.62+0.12+4.8%€2.55€2.73€2.5412,134
€2.50+0.02+0.8%€2.50€2.50€2.50184
€2.48-0.04-1.6%€2.53€2.53€2.48106
€2.52-0.01-0.4%€2.50€2.52€2.501,103
€2.53+0.07+2.8%€2.57€2.57€2.50109
€2.46-0.06-2.4%€2.54€2.58€2.465,044
€2.52+0.01+0.4%€2.58€2.58€2.42400

Splits

1 split · XETR:HPHA · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
Ticker
Stuttgart:HPHA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All Heidelberg Pharma AG news

Heidelberg Pharma AG on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 17 in all · newest Nov 4, 2026 · oldest 2025
Decks
25 decks · latest Mar 26, 2026

Where Heidelberg Pharma AG is listed

ListingExchangeCountryCurrency
Xetra:HPHA · Home listingXetraGermanyEUR
gettex:HPHAgettexGermanyEUR
Tradegate:HPHATradegateGermanyEUR
LS Exchange:A11QVVLS ExchangeGermanyEUR
LSE:0QW5LSEUnited KingdomEUR
Lang & Schwarz:A11QVVLang & SchwarzGermanyEUR
Frankfurt:HPHAFrankfurtGermanyEUR
Stuttgart:HPHA · This pageStuttgartGermanyEUR
Dusseldorf:HPHADusseldorfGermanyEUR
Hamburg:HPHAHamburgGermanyEUR
Munich:HPHAMunichGermanyEUR
Aquis:HPHADAquisUnited KingdomEUR
Aquis:HPHADAquisUnited KingdomEUR
BX Swiss:HPHABX SwissSwitzerlandCHF
Turquoise:HPHADTurquoiseUnited KingdomEUR
VIE:HPHAViennaAustriaEUR

Valuation

EV/sales 8.0× against a median of 128×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026

Enterprise value
€74.49M EUR
P/E
Loss
EV/sales
8.0×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
79.5%
Operating margin
−331.5%
Net margin
−320.9%
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Heidelberg Pharma AG · XETR:HPHAUS$103.2MUS$81.75Mn/a8.0×n/an/a−320.9%n/an/a
Nykode Therapeutics ASA · OSL:NYKDUS$107.0MUS$62.24Mn/an/an/a1.3×n/a0.0×n/a
JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126US$105.3MUS$84.72Mn/a2.0×n/a1.6×−195.8%0.6×n/a
Genelux Corporation · NASDAQ:GNLXUS$104.3MUS$93.85Mn/a11,732×n/a11.4×n/a0.0×1.52
Cardiol Therapeutics Inc. Class A · TSX:CRDLUS$103.4MUS$83.06Mn/an/an/a5.4×n/a0.0×1.45
Foghorn Therapeutics Inc. · NASDAQ:FHTXUS$103.1M−US$9.22M10.9×−0.1×−2.5×n/a8.4%n/a1.57
Vivani Medical, Inc. · NASDAQ:VANIUS$102.8MUS$88.24Mn/an/an/a7.8×n/a0.0×0.93
Paradigm Biopharmaceuticals Ltd. · ASX:PARUS$101.6MUS$96.33Mn/a1,816×n/a44.2×n/a2.2×n/a
Innate Pharma SA Class A · EURONEXT:IPHUS$101.5MUS$111.7Mn/a36.5×n/an/an/an/an/a
BRIM Biotechnology, Inc. · TWSE:6885US$100.3MUS$70.71Mn/a220×n/a2.1×n/a0.0×n/a
Minerva Neurosciences, Inc · NASDAQ:NERVUS$99.67MUS$22.73Mn/an/an/an/an/an/a1.68
Median of the othersUS$103.0MUS$83.89M10.9×128×−2.5×5.4×−93.7%0.0×1.52

Forecasts

Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
6.75 EUR · Analysts' mean
EPS, year to Nov 2026
-0.52 · 1 analyst
Revenue, year to Nov 2026
10M · 1 analyst

Team and board

Officers

OfficerRole
Dongzhou Jeffery LiuChief Executive Officer
Peter WillingerChief Financial Officer
Jörg KemkowskiChief Operating Officer
Sylvia WimmerSenior Director Corporate Communications
George BadescuChief Business Officer
Yan XiaDirector of ADC Research Center

Board

DirectorRole
Karl Benedikt BiesingerChairman
Jack Yefei LingDeputy Director of Finance International Business Department
Klaus Schollmeier
Mathias HothumDeputy Chairman

Events

QuarterResultsShare move
Q1 2026Mar 26, 2026+3.1%
Q4 2025Jan 28, 2026−5.7%
Q3 2025Oct 9, 2025+0.6%
Q2 2025Jul 10, 2025 · Before open+3.3%
Q1 2025Apr 24, 2025 · Before open+3.3%
Q4 2024Jan 29, 2025−1.2%
Q3 2024Oct 10, 2024 · Before open+4.1%
Q2 2024Jul 12, 2024 · Before open+0.4%
Q1 2024Apr 25, 2024 · Before open−0.3%
Q3 2023Oct 12, 2023 · Before open−0.3%
All 18 quarters
QuarterResultsShare move
Q2 2023Jul 13, 2023 · Before open+0.6%
Q1 2023Apr 13, 2023 · Before open−2.1%
Q3 2022Oct 13, 2022 · After close+0.8%
Q2 2022Jul 12, 2022 · Before open0.0%
Q1 2022Mar 24, 2022+3.1%
Quarter to Aug 31, 2021Oct 7, 2021+9.1%
Quarter to May 31, 2021Jul 8, 2021−0.7%
Quarter to Feb 28, 2021Apr 20, 2021−4.4%

Open Events

Decks

DeckKindSlidesDate
FY2025 Earnings PresentationEarnings19 slidesMar 26, 2026
Hamburger Investorentage 2026Conference25 slidesFeb 5, 2026
Investor Presentation (January 2026)Investor deck19 slidesJanuary 2026
16th World ADC Conference San Diego (November 2025)Conference25 slidesNovember 2025
Eigenkapitalforum 2025Conference26 slidesNovember 2025
Corporate Update (September 2025)Corporate update10 slidesSep 25, 2025
International Myeloma Society 22nd Annual Meeting & Exhibition 2025Conference16 slidesSep 20, 2025
Investor Presentation (September 2025)Investor deck44 slidesSeptember 2025
Investor Presentation (August 2025)Investor deck43 slidesAugust 2025
Investor Presentation (June 2025)Investor deck41 slidesJune 2025
All 25 decks
DeckKindSlidesDate
Bio€quity 2025Conference14 slidesMay 13, 2025
German Spring Conference 2025Conference25 slidesMay 12, 2025
FY2024 Earnings PresentationEarnings24 slidesMar 24, 2025
Investor Presentation (February 2025)Investor deck42 slidesFebruary 2025
International Myeloma Society 21st Annual Meeting & Exhibition 2024Conference13 slidesSep 25, 2024
FY2023 Earnings PresentationEarnings21 slidesMar 25, 2024
Inv€$tival Showcase 2023Conference21 slidesNov 13, 2023
Deutsche Biotechnologietage 2023Conference20 slidesMar 28, 2023
Inv€$tival Showcase 2022Conference19 slidesNov 14, 2022
FY2021 Earnings PresentationEarnings25 slidesMar 24, 2022
FY2020 Earnings PresentationEarnings28 slidesMar 25, 2021
German Equity Forum / EKF 2020Conference26 slidesNovember 2020
Investor Presentation (August 2019)Investor deck32 slidesAugust 2019
Investor Presentation (November 2018)Investor deck31 slidesNov 19, 2018
Investor Presentation (July 2018)Investor deck31 slidesJuly 2018

Open Decks

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.46M6.85M9.86M18.5M2.90M8.49M7.31M3.67M1.90M1.36M
Cost of revenue2.64M1.78M3.25M4.68M4.71M5.60M3.74M2.21M956.7K809.1K
Gross profit-1.19M5.07M6.61M13.8M-1.81M2.89M3.57M1.46M943.3K552.9K
Research and development38.8M21.8M28.1M26.4M18.8M18.3M10.9M10.7M9.32M6.12M
Selling, general and administrative7.61M6.74M5.25M4.82M3.99M3.58M3.14M2.97M2.75M1.95M
Operating income-47.4M-20.7M-21.2M-17.2M-25.1M-18.6M-10.4M-11.7M-10.8M-6.36M
Depreciation and amortization2.82M871.2K879.0K756.6K802.9K733.9K546.6K369.0K406.2K279.9K
EBITDA-44.6M-19.8M-20.3M-16.4M-24.3M-17.8M-9.82M-11.3M-10.3M-6.08M
Interest expense4.91K141.5K761.6K840.0K494.0K13.6K220.9K0218.0K20.0K
Income before tax-41.2M-19.4M-20.3M-17.8M-26.1M-18.4M-10.1M-11.7M-11.0M-6.38M
Income tax1.05M11.92M494.5K4.56K5.01K570.5K417.4K9.45K
Net income-42.3M-19.4M-20.3M-19.7M-26.1M-18.4M-10.1M-11.7M-11.0M-6.39M
Earnings per share, basic-0.91-0.42-0.44-0.53-0.80-0.61-0.36-0.41-0.76-0.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents15.0M29.4M43.4M81.3M6.14M4.98M9.88M19.4M30.4M4.57M
Short-term investments-30.0K-34.9K-34.9K-25.3K-35.3K-15.0K
Receivables2.35M5.95M2.32M1.45M1.02M1.23M1.41M400.9K263.5K225.2K
Inventory10.6M11.8M10.5M4.59M745.9K229.8K237.7K177.6K178.0K190.2K
Current assets28.3M47.6M56.6M87.9M9.01M7.52M11.6M20.3M31.2M4.99M
Property, plant and equipment3.67M3.11M2.43M1.95M1.30M1.27M
Goodwill6.11M6.11M6.11M6.11M6.11M6.11M6.11M6.11M6.11M6.11M
Total assets38.1M60.7M70.4M100.6M21.7M19.6M23.0M31.2M41.5M15.2M
Accounts payable7.16M5.55M7.88M3.05M903.0K2.81M1.01M405.5K1.50M132.1K
Current liabilities11.2M8.00M19.8M27.9M14.9M6.63M6.46M5.31M4.46M5.48M
Total debt1.16M22.0M5.83M16.0M10.6M202.7K3.75M
Total liabilities49.1M29.9M21.0M33.9M15.0M6.73M6.70M5.31M4.47M5.49M
Shareholders' equity-10.9M30.9M49.3M66.6M6.70M12.9M16.3M25.9M37.0M9.76M
Shares outstanding46.7M46.6M46.6M37.2M32.5M29.9M28.2M28.2M14.4M28.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-31.6M-29.6M-33.7M-8.86M-26.6M-17.9M-8.56M-9.98M-7.94M-6.53M
Capital spending-128.7K-456.0K-959.9K-612.9K-1.39M-1.43M-963.2K-1.00M-416.1K-537.9K
Free cash flow-31.7M-30.0M-34.6M-9.48M-28.0M-19.3M-9.52M-11.0M-8.36M-7.07M
Cash from investing-135.0K-449.1K5.85M-597.6K-1.40M-1.29M-975.8K-1.00M-416.1K-537.9K
Cash from financing18.3M16.1M-10.1M84.0M29.2M14.3M-114.3M34.2M10.3M
Share buybacks-755.7K
Change in cash-14.4M-14.0M-37.9M75.2M1.16M-4.90M-9.56M-10.9M25.8M3.27M

Open Financials

Cap table

Built by 6ix from Heidelberg Pharma AG’s releases

Common shares
46,784,317
Fully diluted
46,784,317

Fully diluted

LineShares
Common shares46,784,317

Share count over time

CountShares
Nov 22, 202646,784,317

Open Cap table

Shareholders

HolderOf the companyAs of
Hopp, Dipl.-Ing. Dietmar44.1%Apr 3, 2025
Hopp, Jonas43.3%Sep 7, 2022
Hopp, David43.3%Sep 7, 2022
Hopp, Oliver43.3%Sep 7, 2022
Hopp, Daniel41.8%Apr 3, 2025
Hu, Kaijun35.0%Sep 6, 2022
von Bohlen und Halbach, Dr. Friedrich18.7%Apr 3, 2025
Hothum, Mathias18.7%Apr 3, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dongzhou Jeffery LiuChief Executive Officer · Since at least Oct 15, 2026
George BadescuChief Business Officer · Since at least Nov 5, 2026
Jack Yefei LingDeputy Director of Finance International Business Department · Since at least Jul 15, 2026
Jörg KemkowskiChief Operating Officer · Since at least Nov 5, 2026
Karl Benedikt BiesingerChairman · Since at least Apr 17, 2026
Klaus SchollmeierDirector · Since at least Mar 26, 2026
Mathias HothumDeputy Chairman · Since at least Mar 26, 2026
Peter WillingerChief Financial Officer · Since at least Oct 15, 2026
Sylvia WimmerSenior Director Corporate Communications · Since at least Oct 15, 2026
Yan XiaDirector of ADC Research Center · Since at least Mar 26, 2026

Open People

Log in to ask 6ix AI your own questions about Heidelberg Pharma AG.